Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Sanyal AJ, Kaplan LM, Frias JP, et al. Nature Medicine 2024;30:2037-2048.
What it found
In participants of the phase 2 obesity trial who had fatty liver (at least 10% liver fat), liver fat fell by 42.9% (1 mg) to 82.4% (12 mg) at 24 weeks vs +0.3% on placebo. Normal liver fat levels were reached by 86% on 12 mg vs 0% on placebo. The fall in liver fat tracked weight loss.
Limitations
Small substudy measuring liver fat on MRI, not liver inflammation or scarring on biopsy. Short term.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.